242 related articles for article (PubMed ID: 25919161)
1. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
Andrus JK; Walker DG
Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
[No Abstract] [Full Text] [Related]
2. Foreword.
Etienne CF
Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
[No Abstract] [Full Text] [Related]
3. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
Molina-Aguilera IB
Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
[No Abstract] [Full Text] [Related]
4. The ProVac initiative and evolving decision support.
Sanderson CF
Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
[No Abstract] [Full Text] [Related]
5. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
Sosler S; Kallenberg J; Johnson HL
Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
[No Abstract] [Full Text] [Related]
6. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
[TBL] [Abstract][Full Text] [Related]
7. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.
Jauregui B; Garcia AG; Bess Janusz C; Blau J; Munier A; Atherly D; Mvundura M; Hajjeh R; Lopman B; Clark AD; Baxter L; Hutubessy R; de Quadros C; Andrus JK
Vaccine; 2015 May; 33 Suppl 1(0 1):A28-33. PubMed ID: 25919170
[TBL] [Abstract][Full Text] [Related]
9. The role of health economic analyses in vaccine decision making.
Black S
Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
[TBL] [Abstract][Full Text] [Related]
10. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
11. Valuing vaccines: deficiencies and remedies.
Bloom DE
Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
[TBL] [Abstract][Full Text] [Related]
12. Costs of routine immunization services in Moldova: Findings of a facility-based costing study.
Goguadze K; Chikovani I; Gaberi C; Maceira D; Uchaneishvili M; Chkhaidze N; Gotsadze G
Vaccine; 2015 May; 33 Suppl 1():A60-5. PubMed ID: 25919177
[TBL] [Abstract][Full Text] [Related]
13. Strategies for decision-making on vaccine use: the French experience.
Loulergue P; Floret D; Launay O
Expert Rev Vaccines; 2015 Jul; 14(7):917-22. PubMed ID: 25913015
[TBL] [Abstract][Full Text] [Related]
14. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
15. Determinants of routine immunization costing in Benin and Ghana in 2011.
Ahanhanzo CD; Huang XX; Le Gargasson JB; Sossou J; Nyonator F; Colombini A; Gessner BD
Vaccine; 2015 May; 33 Suppl 1():A66-71. PubMed ID: 25919178
[TBL] [Abstract][Full Text] [Related]
16. Examining the cost of delivering routine immunization in Honduras.
Janusz CB; Castañeda-Orjuela C; Molina Aguilera IB; Felix Garcia AG; Mendoza L; Díaz IY; Resch SC
Vaccine; 2015 May; 33 Suppl 1():A53-9. PubMed ID: 25919175
[TBL] [Abstract][Full Text] [Related]
17. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
[TBL] [Abstract][Full Text] [Related]
18. Expanding access to non-traditional vaccines: a perspective from Indonesia.
Suwantika AA; Postma MJ
Expert Rev Vaccines; 2014 Dec; 13(12):1419-21. PubMed ID: 25147940
[TBL] [Abstract][Full Text] [Related]
19. The drivers of facility-based immunization performance and costs. An application to Moldova.
Maceira D; Goguadze K; Gotsadze G
Vaccine; 2015 May; 33 Suppl 1():A72-8. PubMed ID: 25919179
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of health economic evaluations of vaccines in Brazil.
Sartori AMC; Rozman LM; Decimoni TC; Leandro R; Novaes HMD; de Soárez PC
Hum Vaccin Immunother; 2017 Jun; 13(6):1-12. PubMed ID: 28129026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]